B. Riley Weighs in on The Joint Corp.’s Q2 2024 Earnings (NASDAQ:JYNT)

The Joint Corp. (NASDAQ:JYNT) – Investment analysts at B. Riley upped their Q2 2024 earnings per share estimates for shares of Joint in a research report issued on Monday, May 6th. B. Riley analyst J. Van. Sinderen now forecasts that the company will post earnings of ($0.04) per share for the quarter, up from their prior estimate of ($0.05). B. Riley has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Joint’s current full-year earnings is $0.13 per share. B. Riley also issued estimates for Joint’s FY2024 earnings at $0.06 EPS and FY2025 earnings at $0.58 EPS.

A number of other equities analysts have also commented on the company. Roth Mkm reissued a “buy” rating and set a $16.00 price target (up from $13.00) on shares of Joint in a research note on Friday, May 3rd. TheStreet downgraded Joint from a “c-” rating to a “d” rating in a research report on Thursday, March 7th. Finally, StockNews.com upgraded shares of Joint from a “hold” rating to a “buy” rating in a research report on Monday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.00.

Joint Stock Down 1.2 %

JYNT opened at $15.93 on Wednesday. Joint has a 52 week low of $7.31 and a 52 week high of $16.39. The firm has a 50-day simple moving average of $12.42 and a two-hundred day simple moving average of $10.31. The company has a market capitalization of $238.54 million, a PE ratio of -21.24 and a beta of 1.58.

Joint (NASDAQ:JYNT) last issued its earnings results on Thursday, March 7th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. The firm had revenue of $30.61 million during the quarter, compared to analyst estimates of $29.63 million. Joint had a negative net margin of 9.24% and a positive return on equity of 3.94%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP grew its stake in Joint by 345.0% in the 3rd quarter. Quantbot Technologies LP now owns 4,170 shares of the company’s stock worth $37,000 after acquiring an additional 3,233 shares in the last quarter. Barclays PLC increased its holdings in Joint by 29.4% during the 3rd quarter. Barclays PLC now owns 13,725 shares of the company’s stock worth $123,000 after purchasing an additional 3,119 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in Joint by 43.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 16,506 shares of the company’s stock valued at $148,000 after purchasing an additional 4,987 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Joint in the 3rd quarter worth $179,000. Finally, Strs Ohio grew its position in shares of Joint by 69.1% during the 3rd quarter. Strs Ohio now owns 25,200 shares of the company’s stock worth $226,000 after buying an additional 10,300 shares in the last quarter. Hedge funds and other institutional investors own 76.88% of the company’s stock.

Joint Company Profile

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.